

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) An agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein), containing a compound having an effect of enhancing the expression and/or function of Dlg (discs large).
2. (Original) The agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 1, wherein the compound having an effect of enhancing the expression and/or function of Dlg (discs large) is at least one member selected from Dlg, Dlg gene and a recombinant vector containing Dlg gene.
3. (Currently amended) The agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 1 ~~or claim 2~~, wherein sFRP is sFRP 2.
4. (Currently amended) An agent for inhibiting tumor formation, containing the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to ~~any one of claims 1 to 3~~ claim 1.
5. (Currently amended) An agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to ~~any one of claims 1 to 3~~ claim 1.
6. (Original) A method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein), comprising enhancing the expression and/or function of Dlg (discs large).
7. (Original) The method of enhancing the expression and/or function of sFRP (secreted

Preliminary Amendment

U.S. Patent Application No. Unassigned

frizzled-related protein) according to claim 6, comprising using at least one member selected from Dlg (discs large), Dlg gene and a recombinant vector containing Dlg gene.

8. (Currently amended) The method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 6 ~~or claim 7~~, wherein sFRP is sFRP2.

9. (Currently amended) A method of inhibiting tumor formation, comprising using the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to ~~any one of claims 1 to 3~~ claim 1.

10. (Currently amended) ~~The A~~ method of inhibiting tumor formation ~~according to claim 9~~, comprising using the method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to ~~any one of claims 6 to 8~~ claim 6.

11. (Currently amended) A method of preventing and/or treating a tumor disease, comprising using the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to ~~any one of claims 1 to 3~~ claim 1.

12. (Currently amended) A method of preventing and/or treating a tumor disease, comprising using the method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to ~~any one of claims 6 to 8~~ claim 6.

13. (Original) A method of identifying a compound, comprising using a non-human mammal that is deficient in one of Dlg (discs large) alleles, wherein the compound is any one of the following:

- (i) a compound having an effect of enhancing the expression and/or function of Dlg;
- (ii) a compound having an effect of enhancing the expression and/or function of sFRP (secreted frizzled-related protein); and
- (iii) a compound that inhibits tumor formation.

14. (Original) A method of identifying a compound, comprising using a cell originating in a non-human mammal that is deficient in one or both of Dlg (discs large) alleles, wherein the compound is any one of the following:

- (i) a compound having an effect of enhancing the expression and/or function of Dlg;
- (ii) a compound having an effect of enhancing the expression and/or function of sFRP (secreted frizzled-related protein); and
- (iii) a compound that inhibits tumor formation.

15. (Currently amended) The method of identifying a compound according to claim 13 or ~~claim 14~~, wherein sFRP (secreted frizzled-related protein) is sFRP2.

16. (Original) A non-human mammal that is deficient in one or both of Dlg (discs large) alleles.

17. (Original) A cell originating in a non-human mammal that is deficient in one or both of Dlg (discs large) alleles.

18. (Original) A method of examining a tumor tissue or a tumor cell, comprising measuring the expression and/or function of Dlg (discs large) in a test tissue or a test cell and detecting reduction or deletion of the expression and/or function in comparison to a normal tissue or a normal cell.

19. (New) The agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 2, wherein sFRP is sFRP 2.

20. (New) An agent for inhibiting tumor formation, containing the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 2.

21. (New) An agent for inhibiting tumor formation, containing the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 3.

22. (New) An agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 2.
23. (New) An agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 3.
24. (New) The method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 7, wherein sFRP is sFRP2.
25. (New) A method of inhibiting tumor formation, comprising using the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 2.
26. (New) A method of inhibiting tumor formation, comprising using the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 3.
27. (New) A method of inhibiting tumor formation, comprising using the method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 7.
28. (New) A method of inhibiting tumor formation, comprising using the method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 8.
29. (New) A method of preventing and/or treating a tumor disease, comprising using the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 2.
30. (New) A method of preventing and/or treating a tumor disease, comprising using the agent for enhancing the expression and/or function of sFRP (secreted frizzled-related protein)

according to claim 3.

31. (New) A method of preventing and/or treating a tumor disease, comprising using the method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 7.

32. (New) A method of preventing and/or treating a tumor disease, comprising using the method of enhancing the expression and/or function of sFRP (secreted frizzled-related protein) according to claim 8.

33. (New) The method of identifying a compound according to claim 14, wherein sFRP (secreted frizzled-related protein) is sFRP2.